A detailed history of Dodge & Cox transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Dodge & Cox holds 13,898,318 shares of BMRN stock, worth $934 Million. This represents 0.59% of its overall portfolio holdings.

Number of Shares
13,898,318
Previous 13,930,493 0.23%
Holding current value
$934 Million
Previous $1.15 Billion 14.82%
% of portfolio
0.59%
Previous 0.72%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$69.02 - $93.84 $2.22 Million - $3.02 Million
-32,175 Reduced 0.23%
13,898,318 $977 Million
Q2 2024

Aug 13, 2024

SELL
$74.43 - $92.22 $4.65 Million - $5.76 Million
-62,450 Reduced 0.45%
13,930,493 $1.15 Billion
Q1 2024

May 14, 2024

SELL
$83.81 - $99.0 $93,867 - $110,880
-1,120 Reduced 0.01%
13,992,943 $1.22 Billion
Q4 2023

Feb 15, 2024

SELL
$76.22 - $98.51 $12.2 Million - $15.7 Million
-159,440 Reduced 1.13%
13,994,063 $1.35 Billion
Q3 2023

Nov 14, 2023

SELL
$85.07 - $94.48 $11.6 Million - $12.9 Million
-136,800 Reduced 0.96%
14,153,503 $1.25 Billion
Q2 2023

Aug 14, 2023

SELL
$86.68 - $100.3 $3.38 Million - $3.91 Million
-39,010 Reduced 0.27%
14,290,303 $1.24 Billion
Q1 2023

May 12, 2023

SELL
$87.74 - $117.27 $4.77 Million - $6.37 Million
-54,350 Reduced 0.38%
14,329,313 $1.39 Billion
Q4 2022

Feb 14, 2023

SELL
$80.93 - $108.63 $31.6 Million - $42.4 Million
-390,300 Reduced 2.64%
14,383,663 $1.49 Billion
Q3 2022

Nov 10, 2022

SELL
$82.16 - $96.94 $19.2 Million - $22.6 Million
-233,100 Reduced 1.55%
14,773,963 $1.25 Billion
Q2 2022

Aug 12, 2022

SELL
$71.48 - $86.85 $2 Million - $2.43 Million
-27,936 Reduced 0.19%
15,007,063 $1.24 Billion
Q1 2022

May 13, 2022

BUY
$74.28 - $92.69 $15.6 Million - $19.5 Million
209,950 Added 1.42%
15,034,999 $1.16 Billion
Q4 2021

Feb 14, 2022

BUY
$71.72 - $91.47 $463,813 - $591,536
6,467 Added 0.04%
14,825,049 $1.31 Billion
Q3 2021

Nov 15, 2021

BUY
$74.77 - $85.47 $53.6 Million - $61.2 Million
716,485 Added 5.08%
14,818,582 $1.15 Billion
Q2 2021

Aug 13, 2021

BUY
$75.51 - $84.79 $170 Million - $191 Million
2,247,789 Added 18.96%
14,102,097 $1.18 Billion
Q1 2021

May 14, 2021

BUY
$74.73 - $90.69 $154 Million - $187 Million
2,057,384 Added 21.0%
11,854,308 $895 Million
Q4 2020

Feb 11, 2021

BUY
$72.61 - $90.2 $151 Million - $187 Million
2,076,701 Added 26.9%
9,796,924 $859 Million
Q3 2020

Nov 13, 2020

BUY
$71.87 - $131.03 $295 Million - $538 Million
4,104,483 Added 113.52%
7,720,223 $587 Million
Q2 2020

Aug 13, 2020

SELL
$79.55 - $124.22 $26 Million - $40.6 Million
-326,768 Reduced 8.29%
3,615,740 $446 Million
Q1 2020

May 14, 2020

SELL
$71.37 - $96.85 $31.9 Million - $43.3 Million
-447,007 Reduced 10.18%
3,942,508 $333 Million
Q4 2019

Feb 13, 2020

BUY
$64.27 - $86.37 $282 Million - $379 Million
4,389,515 New
4,389,515 $371 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.5B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Dodge & Cox Portfolio

Follow Dodge & Cox and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dodge & Cox, based on Form 13F filings with the SEC.

News

Stay updated on Dodge & Cox with notifications on news.